Sask. expands coverage for 2 drugs used to treat ovarian cancer

The Saskatchewan government has expanded its provincial drug plan to include Keytruda and Elahere for the treatment of advanced or platinum-resistant ovarian cancer. This policy change provides new options for patients who previously struggled to access these expensive immunotherapy treatments.
Why it matters
Demonstrates the impact of provincial healthcare policy on patient outcomes and the financial burden of specialized cancer treatments.
Within three months of ending treatment, her cancer was back and her options were limited.
“It’s hard managing day-to-day going through your treatments every week, knowing that your options are so limited,” Flaman, 55, said.
This spring, Flaman was able to start taking Keytruda, an immunotherapy treatment shown in clinical studies to delay ovarian cancer from progressing and help women live longer.
But the drug wasn’t covered under Saskatchewan’s drug plan. Flaman said she was only able to take it because she received funding from the drug company and coverage under her work’s medical plan.
“Without this funding I never would have been able to continue these treatments,” Flaman said.
Fertility program offers future choices for 12-year-old N.W.T. cancer patient
Starting Dec. 1, 2026, women in Saskatchewan who meet certain medical criteria will have Keytruda and Elahere, another medication used to treat ovarian cancer, covered under the province’s drug plan.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in